evolocumab

all catalysts(0)

nothing on the calendar yet

News(7)

• Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
  The CEO spoke with BioPharma Dive about convincing investors to buy into the first gene editing IPO in more than two years.
  biopharma_dive · 4d ago
• Amgen’s MariTide stands alone after obesity cull while analysts seek more M&A
  Amgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future bus…
  biospace · 9d ago
• Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
  In vivo gene editing outfit Scribe Therapeutics has priced its IPO at $128.7 million, surpassing the $96 million goal set out earlier this week.
  fiercebiotech · 22d ago
• Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
  Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing.
  fiercebiotech · 26d ago
• Merck wins first approval of a PCSK9 cholesterol pill
  The speedy clearance of Lipfendra is an important milestone for Merck and the result of a controversial voucher program put in place by former FDA commissioner Marty Makary.
  biopharma_dive · 29d ago
• Merck dives into cholesterol with first FDA approval for oral PCSK9 inhibitor
  Merck’s once-daily pill is the first oral PCSK9 inhibitor to hit the market for high cholesterol, beating AstraZeneca in the race to develop more accessible treatment options.
  biospace · 29d ago
• Gene editing developer Scribe plots an IPO
  The California drugmaker, which has collaborations in place with Biogen, Sanofi and Eli Lilly, could be the 14th biotech to go public in 2026.
  biopharma_dive · 1mo ago